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Background: A decision of the Federal Joint Committee Germany in 2008 stated that negative pressure wound
therapy is not accepted as a standard therapy for full reimbursement by the health insurance companies in
Germany. This decision is based on the final report of the Institute for Quality and Efficiency in Health Care in 2006,
which demonstrated through systematic reviews and meta-analysis of previous study projects, that an insufficient
state of evidence regarding the use of negative pressure wound therapy for the treatment of acute and chronic
wounds exists. Further studies were therefore indicated.
Methods/design: The study is designed as a multinational, multicenter, prospective randomized controlled,
adaptive design, clinical superiority trial, with blinded photographic analysis of the primary endpoint. Efficacy and
effectiveness of negative pressure wound therapy for wounds in both medical sectors (in- and outpatient care) will
be evaluated. The trial compares the treatment outcome of the application of a technical medical device which is
based on the principle of negative pressure wound therapy (intervention group) and standard conventional wound
therapy (control group) in the treatment of subcutaneous abdominal wounds after surgery. The aim of the SAWHI-
VAC® study is to compare the clinical, safety and economic results of both treatment arms.
Discussion: The study project is designed and conducted with the aim of providing solid evidence regarding the
efficacy of negative pressure wound therapy. Study results will be provided until the end of 2014 to contribute to
the final decision of the Federal Joint Committee Germany regarding the general admission of negative pressure
wound therapy as a standard of performance within both medical sectors.
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The medical problem
Wound healing impairment after surgical procedures is a
common problem in health care. Complications associated
with surgical incisions range from the annoying to the life
threatening, and can be more common and serious than
those related to the primary surgical procedure. These
complications include wound healing disorders caused
by factors due to the surgical procedure itself, by patient-
related factors, or both. These factors are typically interre-
lated, complex in nature, and often difficult to prevent or to
treat successfully. The most common post-operative wound
healing impairments are seroma or hematoma, necrosis
of wound margins or adjacent soft tissue, infections, all
with potential to cause dehiscence of the primarily closed
wound. The occurrence of wound healing impairment
of the abdominal wall represents a multidisciplinary,
treatment- and cost-intensive problem in clinical life
whether it is caused by infectious or non-infectious fac-
tors [1-3]. Only a few clinical trials have been conducted
regarding the use of negative pressure wound therapy
(NPWT) for subcutaneous abdominal wound healing
impairment [4-7] or for example, the adjunctive manage-
ment of abdominal wounds with exposed and known in-
fected synthetic mesh [8]; thus, a randomized controlled
clinical trial (RCT) of high quality that is able to make a
statement concerning efficacy and effectiveness of this
innovative therapy option is still lacking.
Vacuum-assisted wound closure (V.A.C.®)
Basic science studies demonstrated positive effects of NPWT
on wound healing [9,10] and many case reports and case
series document broad use of V.A.C.® (http://www.kci-
medical.co.uk/uk-eng/home) in various clinical settings [11].
Regarding the clinical results and mechanisms of action
of NPWT, the literature provides evidence with regards to
V.A.C.® Therapy’s effectiveness in chronic wounds such
as in diabetic foot wounds, pressure ulcers and lower
extremity ulcers [12]. Additionally, V.A.C.® Therapy is used
in the treatment of a variety of acute wounds, including
abdominal wounds [13], surgical and dehisced wounds
[13-15], grafts and flaps [16,17], deep sternal wounds
[18-20] and partial thickness burns [21,22].
Recent history
When compared to standard conventional wound therapy
(SCWT), most of the published literature confirms the
advantage of negative pressure wound therapy (NPWT),
also called vacuum assisted wound closure, but sufficient
proof of efficacy and effectiveness is lacking [12,23]. The
Federal Joint Committee (G-BA) is the highest decision-
making body of the joint self-government of physicians,
dentists, hospitals and health insurance funds in Germany.
The G-BA faced this situation by commissioning a reporton efficacy and effectiveness of NPWT by the Institute for
Quality and Efficiency in Health Care (IQWiG). The final
IQWiG-reports [24,25] concluded that, in spite of some
indications that NPWT may improve wound healing,
the methodological quality of the so far performed trials is
unsatisfactory and thus the body of evidence available is
insufficient, more specifically in the post-acute care setting.
In 2011, Peinemann and Sauerland updated the systematic
literature review [26] and concluded that although there
may be a positive effect, clear evidence for efficacy and
effectiveness of NPWT is still missing and RCTs of high
quality are still needed to evaluate the benefit of this wound
treatment option. Since the updated review, only a few RCTs
on NPWT with the objective to achieve complete wound
closure have been performed [27,28]. Thus, there is still a
need for a RCT of high quality to contribute to the decision
about the benefit of the use of NPWT for wound healing.
Study objectives and purpose
This RCT was designed to evaluate the efficacy and effect-
iveness of V.A.C.® Therapy for the treatment of subcutane-
ous abdominal wound healing impairment after surgery.
Furthermore it will collect data that will provide a basis for
subsequent efficiency analyses. Moreover, this trial seeks to
evaluate the use of V.A.C.® Therapy in the acute to post-
acute environment, particularly because wound healing oc-
curs across the continuum of care and often continues after
a patient is released from the hospital to homecare or other
community-based care. Thus, there is a need to identify the
outcomes and benefits of V.A.C.® Therapy when compared
to SCWT when used across these care settings.
This trial is designed to comply with all quality re-
quirements of IQWiG and G-BA as well as other European
authorities.
Study results aspire to contribute to the benefit assess-
ment of the IQWiG and the final decision of the G-BA re-
garding the eligibility of V.A.C.® Therapy to be a standard
treatment recognized by German health insurance com-
panies for full reimbursement in both medical sectors.
Methods/design
The SAWHI-V.A.C.®-study is designed as a multinational,
multicenter, randomized controlled, clinical superiority trial,
with blinded photographic analysis of the primary endpoint.
The trial will be performed in Germany, the Netherlands,
Belgium, United Kingdom and Austria.
Phase and classification of the trial
The study is classified as an examination of the clinical
application of a CE-marked medical device with risk
category IIb.
According to the German Medical Device Act (MPG)
the trial is classified as an exemption to clinical investiga-
tion according to section (§) 23b MPG. This is due to the
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only be operated within intended use and there will be
no additional invasive or otherwise straining examina-
tions. Examination results will only be documented if
collected within clinical routine.
Ethical approval of the main ethical committee (EC):
Ethical Committee of the University of Witten-Herdecke,
has been fully granted without any conditions. Due to
performing the trial according to section (§) 23b MPG,
further participating centers in Germany will only receive
a consultation for the respective main clinical investigator
according to professional law. Ethical approval of par-
ticipating centers in Germany is not applicable. Fur-
thermore, until the actual time point, full EC approval
was granted by the EC of the Academisch Ziekenhuis
Maastricht (Netherlands) and by the NRES Committee
East Midlands - Leicester, England (NHS). From each trial
participant, a written informed consent will be obtained
under the conditions set forth in ICH-GCP guidelines.
Randomization
Randomization to treatment arms will be performed at
a 1:1 ratio. Randomization will be performed via a cen-
tralized system with an Internet-based tool. Patients
will be randomized dynamically. The permuted block
sizes will randomly vary between 2, 4, and 6.
Stratification
Stratification will take place by study center and then
also subsequently by wound size (cm3) within study center.
Wound size categories or strata to be considered will be
wounds ≤ 60 cm3 and wounds > 60 cm3.
Primary endpoint
The primary endpoint of this trial is defined as time
(number of days) to achieve complete wound closure in
study participants where closure was observed on or be-
fore day 42 and was confirmed to have been sustained
for a minimum of 14 subsequent days. Complete wound
closure is defined as 100% epithelialization, no drainage
from the wound, no need for adjuvant therapy or dress-
ing and no presence of sutures. Complete wound closure
has to be confirmed after a minimum of 14 consecutive
days. The clinically determined primary endpoint will be
verified through blinded assessment of wound photos by
observers that are independent from the clinical trial.
Secondary clinical endpoints
The incidence of wound closure achieved within each
treatment arm will be evaluated after a maximum study
observation/treatment period of 42 days. These wound
closures have to be confirmed as being sustained for a
minimum of 14 subsequent days. This will be conducted
via blinded photographic analysis. Recurrence of woundopening after initial closure and confirmed wound clos-
ure will be assessed and compared between the treat-
ment groups. Reduction of wound size over time will be
evaluated using reduction in wound volume and wound
surface area over time.
Safety endpoints
Incidence of serious adverse events (SAEs) including mor-
tality of any cause within 132 days from the time of initi-
ation of therapy, incidence of device-related events (ADEs),
wound-related adverse events (AEs) and incidence of
unsustained closure within the study treatment time of
42 days are considered to be safety endpoints of this trial.
Patient reported outcome
Instruments and assessments used for measurement of
Patient Reported Outcome (PRO) of the SAWHI-study
focus on the constructs ‘Quality of life’ (QoL) and ‘Reports
and Ratings of health care’ (Patient Satisfaction). QoL
is measured by using a multidimensional questionnaire
assessing a combination of aspects of impairments and
disability and reflects a patient’s health status. QoL will
be measured using the SF-36v2 questionnaire at Day
42 (end of maximum treatment/observation time) or at
wound closure visit, hospital discharge, and at the general
follow-up visit. Patient Satisfaction covers a structured
participant self-report and a valuation of the disease-
specific healthcare [29]. Furthermore, this point includes
participants’ valuation of the treatment result with regard
to scarring and the cosmetic result. The participant will be
asked about the general estimation of therapy progression
and detailed treatment satisfaction. This item will be evalu-
ated by using a self-constructed questionnaire on the basis
of specific scales of the Cologne Patient Questionnaire [30].
The Cologne Patient Questionnaire has formerly been used
to develop a theory-based and empirically tested instru-
ment for measuring patient-reported ‘psychosocial care
by physicians’ [31] and represents an ideal basis for de-
velopment of a specific questionnaire for participant sat-
isfaction of this trial. Patient Satisfaction will be evaluated
during general follow-up visits. Furthermore, during study
visits, participants will be asked to provide their assess-
ments of pain with a numerical rating scale. Participants
will be asked to provide an estimate of their wound-
associated pain of the last 24 hours.
Health economic endpoints
Additionally to the evaluation of clinical treatment effect-
iveness, a prospective assessment of health economic issues
will be performed. This evaluation includes the assessment
of parameters relevant for inpatient and outpatient resource
use (resource utilization). A detailed baseline data acquisi-
tion regarding underlying disease and intervention will cre-
ate the basis for further assessments of health development
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documented using a separate, standardized case report
form (CRF) sheet. The category direct medical resource use
(direct medical costs) includes the resource use that results
directly from wound treatment or wound-specific therapy.
General and specific clinical diagnostics, relevant medi-
cation (in particular analgesics and antibiotics), specific
wound therapy, number and type of debridement, residen-
tial treatment and medical attendance, outpatient treatment
and medical attendance will be analyzed. Surgical reinter-
ventions and rehospitalizations are especially a burden for
health care and will be evaluated during the study. Resource
use (cost) that is not directly associated with disease treat-
ment is considered as indirect resource use (cost). This in-
cludes the evaluation of restrictions of productivity besides
absence from the workplace (activities of daily living) and
nonproductive time for those who are gainfully employed.
Blinding
Due to the physical differences between the treatment regi-
mens, it is not possible to blind either participant or phys-
ician to the treatment. To address issues of blinding, wound
photo documentation will be obtained during the trial and
confirmation of wound closure will be assessed via blinded
assessment of photos by independent observers, which will
serve as the method of primary endpoint analysis.
Setting
This multicenter study will be conducted in abdominal
surgical hospital departments with the required manpower
as well as structural and scientific qualifications. For both
treatment arms, a maximum treatment time of 42 days to
achieve complete wound closure shall be provided to cover
80% of participants, whether healing occurs by secondary
or delayed primary closure [4]. All participants will be
followed up for 90 days (three months) after the maximum
treatment time, independent of whether a wound closure
was achieved or not, or at which time point within the
maximum timeframe for active treatment the wound clos-
ure was achieved. Thus, a general follow-up date for all
study participants will be at Day 132. A follow-up period of
three months after the active treatment period allows for
an assessment of recurrence of the wound dehiscence or
impairment as well as an adequate assessment of health
economic relevant issues. Participants who have not
achieved wound closure after 42 days will be seen at 45 days
(six weeks) after the end of active treatment time (Day 87).
This timeframe allows for a complete assessment of wound
progression after study treatment and an assessment of
wound closure that is achieved later than Day 42. Figure 1
gives an overview of the study flow. Study therapy will be
started on participants in ambulatory care or in hospital
and may be continued in ambulatory care. Due to the scope
of the trial to evaluate outcomes and benefits of V.A.C.®Therapy when compared to SCWT when used across these
care settings, all patients at the time point of randomization
or inclusion, or during the active treatment period of
42 days that are eligible for outpatient care and have
reasonable access to it, have to be transferred to out-
patient care. The transfer of appropriate patients to out-
patient care will be monitored and a missing transition
that is not due to the medical condition of the patient or
the need to provide the optimal treatment will be consid-
ered to be a protocol violation.
Type of participants
Diagnosis
There are two categories of wound patients with distinct
post-surgical open abdominal wound diagnoses that will
qualify for this study. Patients with primarily closed post-
surgical abdominal wounds without fascial dehiscence that
develop a spontaneous wound dehiscence or require an
active reopening of the wound by the treating physician
may be included in the trial. Furthermore, patients with
open post-surgical abdominal wounds without fascial
dehiscence that cannot be closed by primary intention
and require further treatment to achieve permanent closure
are appropriate for trial participation.
Inclusion and exclusion criteria
Only patients meeting all inclusion criteria and no exclu-
sion criteria should be included in the study. No deviation
will be granted for waiver of inclusion criteria and/or exclu-
sion criteria. Table 1 gives an overview of the inclusion and
exclusion criteria of the trial. Patients to be included in
the SAWHI-study must have a post-surgical abdominal
wound with intact fascia and be willing and able to
provide written informed consent. At time of inclusion
the minimum wound size must be eligible for both possible
study treatment arms according to the therapeutic re-
quirements of the respective randomized treatment arm.
Inclusion, randomization, adequate wound pre-treatment
(debridement) and start of therapy must be performed
within 48 hours after reopening of the wound, diagnosis
of non-closable wound or in case of spontaneous wound
dehiscence.
Exclusion criteria
A patient unable or unwilling to comply with the protocol
and study-related requirements, to sign the informed con-
sent form, or to have their legally authorized representative
act as a surrogate will be excluded from study participation.
If a potential study patient, in the estimation of the clin-
ical investigator, is unable to comply, the patient must
be excluded from participation.
If the defect of the abdominal fascia is present at the
time point of initial diagnosis or reopening of the wound,
but can be closed before randomization but within the
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Figure 1 SAWHI-study flow chart. The figure shows the SAWHI overall study flow.
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the study. Any concomitant therapies or procedures
deviating from the clinical standard wound treatment
or with investigational character (for example, use of
hyperbaric oxygen therapy) are not allowed ≤ 30 days prior
to screening. The need for concomitant therapies or
procedures that, in the opinion of the treating physician,
would directly affect wound healing, or the ability to
observe wound healing, is an exclusion criterion for trial
participation. Concurrent participation in another trial
that directly interferes with, or is likely to interfere inthe foreseeable future with study procedures, patient’s
compliance, wound healing or targeted endpoints is
not allowed for participants of this trial.
Intervention and comparison
This study is designed to evaluate treatment effects of a
medical device in comparison to control therapy. Trial
intervention is wound treatment with V.A.C.® using the
basic principle of NPWT (Figure 2). The V.A.C.® therapy
system is a non-invasive wound therapy system that uses
controlled, localized negative (that is, subatmospheric)
Table 1 SAWHI inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Written informed consent Age <18 years
Diagnosis of post-surgical subcutaneous abdominal wound
healing impairment
Expected non-compliance with study procedures, visit schedule,
and follow-up
Minimum wound size eligible for both possible study treatment arms Pregnancy
Inclusion, randomization and start of therapy within 48 hours after
initial diagnosis
Present or nonclosable defect of the abdominal fascia
Any pre-existing or ongoing organ system failure, that cannot
be stabilized or solved by appropriate medical treatment
Necrotic tissue with eschar present
Non-enteric and unexplored fistulas
Malignancy of the wound
Use of any other device based on the principle of negative pressure
wound therapy on the study wound within≤ 8 days prior to screening
Competing therapy and procedures at the time of inclusion
The table shows the inclusion and exclusion criteria for SAWHI-study participants.
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healing in chronic and acute wounds. The V.A.C.® ther-
apy system label has been on the market since 1995 and
bears the CE mark and includes the trade name and ad-
dress of the manufacturer, the batch code, and all other
essential information according to European Union
(EU) Directive 1993/42/EEC. The V.A.C.® therapy systemFigure 2 Vacuum Assisted Closure (V.A.C.®). The figure shows the foam
mechanisms to promote granulation tissue formation. The Sensa T.R.A.C.™
provides intermittent and continuous therapy with integrated patient safet
related publications.promotes wound healing through optimization of blood
flow, decreasing local tissue edema, and removing excessive
fluid from the wound bed. These physiologic changes facili-
tate the removal of bacteria from the wound. Additionally,
the cyclical application of subatmospheric pressure alters
the cytoskeleton of the cells in the wound bed through
microstrain, triggering a cascade of intracellular signals thatdressing fitted into the wound that helps to provide the necessary
pad regulates pressure at the wound site and the V.A.C.® Therapy Unit
y features. Copyright by KCI with permission for use for study
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of granulation tissue. Moreover, this system has been
shown to also cause macrostrain, bringing the edges of the
wound closer and also stimulating wound bed granulation.
[11] The V.A.C.® therapy devices that will be used in this
study include the ActiV.A.C.® Therapy System, InfoV.A.C.®
Therapy System, V.A.C. Freedom® ,V.A.C. Via® and V.A.C.
Ulta® Therapy Systems. All V.A.C.® Therapy devices to be
utilized in this study bear the CE mark and will be operated
within normal conditions of use. In addition, all dressings
to be used in the treatment group (V.A.C.® Therapy)
bear the CE mark and will be used according to clinical
guidelines. The use of the allocated V.A.C.® Therapy
System should be performed according to the clinical
guidelines released by KCI. Devices can be used with the
black GranuFoam™ Dressing, V.A.C. GranuFoam Silver®
Dressing, or V.A.C.® White Foam Dressing as indicated by
the treating physician. Dressing changes are recommended
to be performed every 48 to 72 hours, no fewer than
three times per week, with frequency adjusted by the
clinician as appropriate. Furthermore any concomitant
therapies or procedures deviating from the clinical
standard wound treatment or with investigational character
(for example, use of hyperbaric oxygen therapy) are not
allowed during the course of the trial.
Incidents, complications or adverse reactions like pain
during dressing changes, maceration, cellulitis or bleeding,
and so on, have been reported only sporadically while using
V.A.C.® therapy for treating acute and chronic wounds.
Potential adverse events can usually be avoided or signifi-
cantly reduced by complying with the basic rules of vacuum
therapy (as detailed in the manufacturer’s instructions
for use and guidelines for the use of V.A.C.® Therapy) as
well as by the use of specifically designed vacuum device
systems [32-34].
Control therapy is defined as any standard conventional
wound therapy (SCWT) according to local clinical stan-
dards. Standard therapy is defined as the currently ac-
cepted and widely used treatment for the respective
wound type, based on the results of past research. Therapy
options for standard wound care are treatments that ex-
perts agree to be appropriate, accepted, and widely used.
Health care providers are obligated to provide patients
with best practice and standard of care.
Type of analysis
The primary efficacy parameter, time to complete wound
closure, will be compared between the two treatment
groups using a log-rank test. In addition, as a supportive
analysis, a Cox proportional hazards regression will also
be used in order to assess if there is a difference between
treatment groups while accounting for the effect of study
center and wound size (appropriate baseline and medical
history parameters will also be considered). The secondaryefficacy parameter, incidence of complete wound closure,
will be analyzed using a chi-squared test comparing
the two treatment groups. As a supportive statistical
analysis, logistic regression will also be implemented.
The logistic regression will include treatment, study center,
and wound size. Reduction in wound area (cm2) and
wound volume (cm3) will be assessed using a three-factor
(treatment group, study center, and time) analysis of covari-
ance with baseline wound area (or volume) recorded at
baseline to be used as a covariate. One planned interim
analysis will be performed when 250 study participants
have completed the first phase of the study. The interim
analysis will validate the assumptions made for the study
sample size calculation and will determine if sample size
re-estimation is warranted.
The results of the SAWHI-V.A.C.®-study will be analyzed
by the intention-to-treat (ITT) approach. The ITT analysis
population will include all randomized participants who
have a valid baseline and at least one valid post baseline
wound assessment (examination). For the ITT analysis
population, participants will be assigned to the treatment
group based on the randomization schedule, regardless of
the treatment actually received. For the analysis of the pri-
mary efficacy endpoint, missing values will be incorporated
as censored values. For secondary endpoints, methods for
imputing missing or partially missing data will be used as
appropriate. The last observation carried forward (LOCF)
method will be used for the analysis of the endpoints
‘incidence of wound closure’; ‘recurrence’ and ‘reduction
of wound size’ in case of study determination or death.
As a secondary approach, a per protocol (PP) analysis will
be performed without patients with any protocol deviations.
Violations of inclusion and exclusion criteria; changes
of randomized therapy; the use of concomitant ther-
apies or procedures deviating from the clinical stand-
ard wound treatment or with investigational character
(for example, use of hyperbaric oxygen therapy) and
dressing changes not performed as recommended to be per-
formed every 48 to 72 hours (no fewer than three times per
week) will be considered as protocol deviations. Further-
more, during analysis, concomitant therapies or procedures
will be evaluated regarding its impact to directly affect
wound healing or the ability to observe wound healing.
Determination of sample size
The primary efficacy endpoint is the time to achieve
confirmed wound closure within 42 days of surgery
(that is, wound confirmed closed after 14 consecutive days).
Time to confirmed wound closure will be presented with
Kaplan-Meier curves and differences between the two
treatment groups will be evaluated with the log-rank
test. Sample size estimation has been performed using
the expected difference in wound closure rates rather
than hazard ratios. Assuming a complete wound closure
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of 12.5% after a treatment time of 42 days, a number of 246
participants per group would be needed (chi-squared test)
to achieve 80% power with α = 0.05. If α = 0.048 due to
one interim analysis (see below) sample size per group
would increase only marginally (n = 249 per group, or
n = 498 in total). Assuming a maximum loss-to-follow-up
rate of 10% for both treatment groups, a total of 550
participants will be required. Up to 600 participants will
be enrolled in this study. The computer program of
Dupont and Plummer was used for sample size calcula-
tion [29]. One interim analysis will be performed when
250 participants complete the first phase of the study,
and type I error rate will be adjusted using the O’Brien-
Fleming method (α = 0.005 for the interim analysis and
α = 0.048 for the final analysis) [35].
The final analysis is planned to be performed with
time-to-event data (survival curves; log-rank test) rather
than wound closure rates. However, since this more de-
tailed approach is able to detect differences more sensitive
than event rates, the calculated sample size is considered
to be sufficiently large.
Discussion
Justification for target study population
Wounds with healing impairment after abdominal surgery
and intact fascia were chosen as the target study population
because they are considered to be a fair representation
of open wound types and also are frequently associated
with the types of comorbidities observed with other types
of open wounds.
Wound closure
Wound closure can be achieved by delayed primary
intention (secondary suture, skin flap, skin graft) or second-
ary intention according to requirements of the participant
and wound in the estimation of the attending physician.
Optimal care for the participant has to be ensured.
Independent from type of closure, criteria for wound
closure have to be reached within a maximum time frame
of 42 days and wound closure has to be confirmed for a
minimum of 14 consecutive days (14 days −0 / + 3).
SAWHI-website, photo documentation platform and
verification of clinical wound size estimation
A study-website has been set up that contains all relevant
information about the trial as well as a personal login area
for each participating study center and a web-based photo
documentation platform for wound photographs of study
participants. The website can be found using the uni-
form resource locator http://www.sawhi.com. Wound
photographs will be uploaded by study sites for each trial
visit. The Wound Healing Analyzing Tool (WHAT) has
been integrated within the platform. A centralized woundanalysis of anonymized photographs (blinded assessment
of wound photos) will be performed, which facilitates the
objective evaluation of wound healing processes. Secondary
endpoints (numerical parameters) like circumference (mm),
area (mm2), maximum length (mm), and height (mm) will
be calculated from the wound image using WHAT whereas
the application of the system also will be performed by
blinded independent assessors.
Data Quality Assurance
In order to guarantee the high quality of the study data
and data retrieval, all participating centers will be visited
on a regular basis onsite by the clinical research associates
(CRAs) according to a predefined monitoring plan. Data
protection rights will be respected. Participant files will
be monitored on a 100% basis to control original data
and to verify accurate data registration and management
(100% source data verification).
Ethical conduct of the study
This study is to be conducted in accordance with the
International Conference on Harmonization (ICH) Harmo-
nized Tripartite Guidelines for Good Clinical Practice 1996,
the European Union (EU) Directive 95/46/EC on the
protection of individuals with regard to the processing
of personal data and on the free movement of such data as
transposed into national law, the EU Medical Device
Directive 93/42/EC as amended by Directive 2007/47/EC as
amended into national law, the International Organization
for Standardization (ISO) 14155 related to AE definitions
and in the spirit of the Declaration of Helsinki concerning
medical research in humans (latest edition).
Publication
Both positive and negative results of the trial will be
disclosed. The results of the trial will be submitted for
publication to peer-reviewed scientific journals and/or
presented at international scientific congresses. The
Principal Coordinating Investigator and the Steering
Committee are responsible for the primary and secondary
publications and/or presentations arising from the study.
KCI guarantees IFOM the publication rights for study
results. KCI is entitled to examine the manuscript prior
to publication and to make comments on it. KCI may
delay publication for up to three months after analyzing
the research results if it is applying for a patent or other
important reasons. All publications will maintain data
protection of participant data as well as data of the par-
ticipating investigators. The publishing of data from a
single study center is permitted after analysis and pri-
mary publication of the final results only. Publication of
study results or data, including data of a single study
center, has to be reviewed and approved by the Steering
Committee, IFOM, and KCI.
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efficiency in health care; ISO: International Organization for Standardization;
ITT: Intention-to-treat; KCI: Kinetic concepts incorporated; LOCF: Last observation
carried forward; MPG: German: Medizinproduktegesetz; : English: German
medical device act; NPWT: Negative pressure wound therapy; PP: Per protocol;
PRO: Patient reported outcome; QoL: Quality of life; RCT: Randomized
controlled trial; SAE: Serious adverse events; SCWT: Standard conventional
wound therapy; V.A.C.®: Vacuum Assisted Closure (registered trade mark);
WHAT: Wound healing analyzing tool.
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